ReviewCurrent cardiology reports2007
Beta-blockers: no longer an option for uncomplicated hypertension.
Review in Current cardiology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?Current cardiology reports · 2011Article
- Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts.American journal of physiology. Heart and circulatory physiology · 2011Article
- Premise, promise, and potential limitations of invasive devices to treat hypertension.Current cardiology reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, beta-blockers, used as first-line agents to treat uncomplicated hypertension, were recommended by national and international guidelines despite a paucity of evidence regarding their cardiovascular benefit. However, evidence from recent trials and meta-analyses has questioned the use of beta-blockers as preferred agents. This article reviews the data available from clinical trials and argues that beta-blockers are less efficacious than other currently available antihypertensive agents for patients with uncomplicated hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.